Onco Actu du 8 novembre 2017

	1. Biologie
NCRI 2017: Understanding cancer evolution [Institute of Cancer Research] Dr Andrea Sottoriva at the NCRI 2017 conference explained what we know about cancer evolution, what we don't know, and what questions we should be asking.
	2.6 Etiologie - Environnement
My Wishlist for the New Head of IARC [The Risk-Monger] The only thing IARC monographs do, in the context of an activist-driven exploitation of social media, is create uncertainty about public health and opportunity for shady actors and fear-mongers.
Parental exposure to hazardous agents tied to eye tumors in offspring [Reuters] The research team studied 282 children with sporadic retinoblastoma, plus 155 of the children’s healthy friends, as well as all the parents. Fathers were asked to report all jobs held in the ten years prior to conception. Mothers reported jobs held the month prior to conception in addition to any jobs they had while pregnant.
WHO seeks new director for cancer agency facing U.S. scrutiny [Reuters] A spokesman for the WHO’s headquarters in Geneva declined to give details on the timing of or reason for the job posting, but said it “should be a regular turnover”. He referred further questions to IARC, but IARC did not respond to Reuters emails.
	3.3 Prévention - Vaccins
Know what’s worse than the risks of getting the HPV vaccine? Getting an HPV-related cancer. Trust me [STAT] Missing from the discussion are the risks of not getting the vaccine. As someone with HPV-related oropharyngeal cancer, I can describe a few of them.
A doctor writes: We need to talk about oral sex and cancer [Irish Times] Unprotected oral sex can result in HPV-associated cancers, a growing health problem.
	3.7 Prévention - Alcool
Alcohol Linked to Cancer According to Major Oncology Organization: ASCO Cites Evidence and Calls for Reduced Alcohol Consumption [ASCO] In addition to raising awareness of the established link between alcohol and cancer—and thereby the opportunity to reduce cancer risk by limiting how much alcohol is consumed—the statement, published in the Journal of Clinical Oncology, also offers some evidence-based policy recommendations to reduce excessive alcohol consumption.
Cancer Doctors Cite Risks of Drinking Alcohol [NY Times] “The message is not, ‘Don’t drink.’ It’s, ‘If you want to reduce your cancer risk, drink less. And if you don’t drink, don’t start,’” said Dr. Noelle LoConte, an associate professor at the University of Wisconsin-Madison and the lead author of the ASCO statement.
Cutting back on alcohol can prevent cancers: experts [Reuters] The call to action from ASCO follows a survey the group commissioned, which found that 70 percent of Americans do not recognize drinking alcohol as a risk factor for cancer.
	4.9 Dép., diag. & prono. - Sein
Breast cancer – can prevention become more personalised? [PHG Foundation] As part of the PROCAS study, researchers have developed a genetic test to assess small variations in a number of genes (single nucleotides polymorphisms, or SNPs), that collectively may increase the risk of breast cancer, and that might be present in women with family history of breast cancer but who do not carry a high-risk BRCA1/2 gene mutation.
	5. Traitements
Study Tracks the Evolution of Treatment Resistance in Metastatic Breast Cancer [NCI] In the study—which was funded by NCI’s Cancer Systems Biology Consortium—researchers performed comprehensive analyses of cancer cells from women with metastatic breast cancer that were collected serially throughout the course of their cancer treatment.
	5.12 Immunothérapies
Cancer treatment response may be affected by gut bacteria [NHS Choices] The findings are of interest, but don't have any immediate implications for cancer treatment.
	5.12.2 Immunothérapies - CAR-T
CAR T-Cell Therapy: Is It Right For You? [Dana-Farber Cancer Institute] Although patient eligibility requirements vary from trial to trial, all trials limit enrollment to patients who are likely to be able to tolerate the sometimes severe side effects of CAR T-cell therapies.
FDA Lifts Hold on Cellectis’s “Off the Shelf” CAR-T, With Caveats [Xconomy] The Cellectis studies are being closely watched because they are some of the most advanced tests of what are known as “allogeneic” CAR-T therapies, whereas the first two approved CAR-T treatments are “autologous” therapies.
	5.12.3 Immunothérapies-combinaisons
Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [BMS] Results also show that patients reported significantly better kidney cancer symptom control in the Opdivo (nivolumab) plus Yervoy (ipilimumab) arm compared to the sunitinib arm.
	5.12.9 Immunothérapies - SITC
Acess SITC 2017 Abstracts [The Sentinel] The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstracts in 2017 for its Annual Meeting, marking a 21 percent increase in submissions compared to last year.
Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting [BMS] Data on key pipeline assets, including late-breaking findings on IDO1 inhibitor BMS-986205 plus Opdivo in advanced cancers, and first disclosures of the Company’s OX40 agonist and anti-CSF1 receptor antibody, will be featured.
	5.2 Pharma
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer [Novartis] The MONALEESA-7 trial met its primary endpoint of progression-free survival (PFS) in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
Novartis cancer drug Kisqali succeeds in late-stage trial [Rfeuters] In the so-called MONALEESA-7 trial, Kisqali (ribociclib) combination therapy met its primary endpoint of progression-free survival in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
	5.2.2 Pharma - Fusions & Acquisitions
Say it with us: IQVIA is the new Quintiles and IMS Health [EndPoints] The decision to merge two otherwise disparate operations signaled a new direction for the clinical outsourcing industry, where consolidation and expansion into new data-driven markets is the name of the game now.
	5.2.3 Pharma - économie
2,300 Lilly Workers, Many In Indiana, Take Buyouts Amid Downsizing [WFYI] More than 12,000 people work for Lilly in Indiana alone. A spokesman says the majority of the 2,300 workers who volunteered for buyouts are among them. They’ll get extra benefits to retire early.
	5.3 Traitements - FDA, EMA, NICE...
EMA gets ready for relocation decision [EMA] With less than two weeks to go before EU Member States select a new host city for the European Medicines Agency (EMA) on 20 November 2017, the Agency prepares itself to immediately start working with the new host country.
	5.3.4 Traitements - AMM (FDA, EMA)
With new FDA nod, Roche's Alecensa set to challenge Pfizer, Novartis in first-line lung cancer [FiercePharma] Roche's lung cancer drug Alecensa had been relegated to patients who'd failed on treatment with one of its rivals, but a new FDA nod is changing all that. It's now approved to treat newly diagnosed patients with ALK-positive disease, and Roche has some Xalkori-beating data to back it up.
	6.1 Observation
Thousands living with advanced cancer, says Macmillan [BBC News] It is the first time that data showing the number of people in England living several years after being diagnosed with stage 4 cancer has been available.
NCDS, health equity and social determinants of health [Marmot Review] There is a rumour going around that poor people are poor because they make poor choices; and that poor people are unhealthy because they make unhealthy choices. This rumour is a myth. It has the causal connection backwards.
Thousands with advanced cancer are surviving two years or more, data shows [The Guardian] The research, revealed on Wednesday at the 2017 National Cancer Research Institute Conference in Liverpool, is based on data from England’s national cancer registry.
IUDs may cut risk of cervical cancer by a third, study indicates [The Guardian] Research from the Keck School of Medicine at the University of Southern California analysed data from several observational studies involving more than 12,000 women worldwide.
Mongolia's liver cancer crisis: 'No other country has a problem like this' [The Guardian] Each year, liver cancer and liver cirrhosis account for 15% of all deaths. Chronic hepatitis is the most common risk factor in developing liver cancer, and 400,000 of Mongolia’s 3 million citizens are diagnosed with a hepatitis virus.
	6.10 Politiques
Brexit with no deal risks chaos in drug supply, report warns [Reuters] “A scenario where the UK leaves without any deal would cause extensive problems for the NHS. It would risk a chaotic disruption to supplies of medical products, and a rise in prices that would push hospitals deeper into deficit,” the report stated.
	6.10.1 Politiques (USA)
Ohio voters reject measure to rein in drug costs [STAT] Tuesday’s vote was the second defeat for the proposal, which was also voted down in California last year. Many voters said they were confused about its impacts on consumers and didn’t feel comfortable supporting it.
	6.6 Publications
Pirate paper website Sci-Hub dealt another blow by US courts [Nature] American Chemical Society wins lawsuit against the site, and could seek to block access to the portal in the United States.